Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell   publishing date : 2020 - 12 - 05    save search
Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting
Published: 2020-12-05 (Crawled : 18:00) - globenewswire.com
ALLO | $3.48 0.58% 0.57% 2M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
therapy positive results phase 3 phase 1 phase 2 t-cell
Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting
Published: 2020-12-05 (Crawled : 15:00) - globenewswire.com
NTLA | $21.57 1.17% 1.16% 1.4M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
crispr leukemia treatment t-cell myeloid leukemia preclinical pre-clinical acute myeloid leukemia
Gainers vs Losers
67% 33%

Top 10 Gainers
KUKE | $2.88 2.49% 7.64% 360K twitter stocktwits trandingview |

CXM 4 | $11.34 -0.44% 4.27% 1.7M twitter stocktwits trandingview |
Information
BSBR | $5.25 2.54% 0.38% 430K twitter stocktwits trandingview |
Finance
JOE 4 | $54.88 1.22% 0.22% 210K twitter stocktwits trandingview |
Finance
MUSA 4 | $417.23 1.06% 0.01% 170K twitter stocktwits trandingview |
Retail Trade
JBI 4 | $15.14 1.34% 0.0% 2.9M twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.